2021
19-OR: Maternal Diabetes Is Associated with Adverse Diabetes Characteristics and Accelerated Onset of Complications in Youth with Type 2 Diabetes (T2D) in TODAY
ISGANAITIS E, SHAH R, CHERNAUSEK S, FARRELL R, GEFFNER M, KEADY J, KELSEY M, TESFALDET B, TRYGGESTAD J, VAN NAME M. 19-OR: Maternal Diabetes Is Associated with Adverse Diabetes Characteristics and Accelerated Onset of Complications in Youth with Type 2 Diabetes (T2D) in TODAY. Diabetes 2021, 70 DOI: 10.2337/db21-19-or.Peer-Reviewed Original ResearchGlycemic controlAccelerated onsetDaiichi SankyoAdverse diabetes outcomesFuture cardiometabolic healthNegative islet autoantibodiesYouth-onset T2D.Type 2 diabetesMothers of participantsNovo NordiskSuccessive NN intervalsHeart rate variabilityGlomerular hyperfiltrationIslet autoantibodiesCardiometabolic healthDiabetes statusMaternal diabetesKidney diseaseDiabetes careDM diagnosisDohme Corp.Diabetes outcomesPrenatal exposureDiabetes characteristicsDiabetic retinopathy
2020
Health Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study
Weinstock R, Braffett B, Songer T, Herman W, Kuo S, Gubitosi-Klug R, Laffel L, McKay S, Siska M, Van Name M, Zeitler P. Health Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study. Diabetes Care 2020, 43: 2469-2477. PMID: 32778555, PMCID: PMC7510035, DOI: 10.2337/dc20-0760.Peer-Reviewed Original ResearchConceptsType 2 diabetesHealth care coverageCare coverageGlycemic controlYoung adultsYouth-onset type 2 diabetesCommunity careYouth-Onset Type 2Medicaid expansionCommercial coverageCommunity diabetes careGovernment coverageDiabetes careDiabetes visitsTreatment optionsMore young adultsNew therapiesType 2DiabetesTODAY cohortCentral laboratoryVulnerable populationsCareCommercial plansHbA
2019
Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes
Hilliard ME, Levy W, Anderson BJ, Whitehouse AL, Commissariat PV, Harrington KR, Laffel LM, Miller KM, Van Name M, Tamborlane WV, DeSalvo DJ, DiMeglio LA. Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 493-498. PMID: 31287721, PMCID: PMC6708264, DOI: 10.1089/dia.2019.0142.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringCGM useDiabetes managementDiabetes careBenefits of CGMYoung childrenGlucose monitoringMean child ageChildren's diabetes careType 1 diabetes managementPainful insertionT1D durationParents of childrenGlucose excursionsImproved sleepClinical strategiesSemistructured qualitative interviewsType 1Parental comfortChild's ageChildrenBehavioural supportMultiple barriersParents' experiencesCaregivers
2018
T1D and T2D Youth in the Pediatric Diabetes Consortium (PDC) Registries—Comparing Clinical Characteristics and Glycemic Control
TAMBORLANE W, CHENG P, GAL R, KOLLMAN C, VAN NAME M, LYNCH J, NELSON B. T1D and T2D Youth in the Pediatric Diabetes Consortium (PDC) Registries—Comparing Clinical Characteristics and Glycemic Control. Diabetes 2018, 67 DOI: 10.2337/db18-1340-p.Peer-Reviewed Original ResearchTarget HbA1c levelT2D youthHbA1c levelsMedtronic MiniMedResidual endogenous insulin secretionHigher mean HbA1c levelsBoehringer Ingelheim GmbHMean HbA1c levelEndogenous insulin secretionOverweight/obesePoor diabetes outcomesChi-square testMann-Whitney UBoehringer Ingelheim PharmaceuticalsT2D durationClinical characteristicsInsulin therapyGlycemic controlT1D patientsDiabetes careDiabetes outcomesRisk factorsC-peptideInsulin secretionLogistic regressionManagement of Hypertension and Hyperlipidemia in Youth with T2D
BEAULIEU L, CHENG P, KATZ M, LAFFEL L, TAMBORLANE W, VAN NAME M, BANSAL N, KOLLMAN C, GAL R. Management of Hypertension and Hyperlipidemia in Youth with T2D. Diabetes 2018, 67 DOI: 10.2337/db18-1342-p.Peer-Reviewed Original ResearchTreatment of hypertensionBoehringer Ingelheim PharmaceuticalsLifestyle changesMedtronic MiniMedBoehringer Ingelheim GmbHPatient-related barriersManagement of hypertensionUrban academic centerEli LillyAdditional cardiovascular diseaseSelf-reported practicesMannKind CorporationSanofi USCVD complicationsLifestyle modificationGlycemic controlPatient adherenceDiabetes careTreatment recommendationsCardiovascular diseaseHypertensionPatient's perspectiveDiabetes InstituteHyperlipidemiaPhysical activity
2016
Future Drug Treatments for Type 1 Diabetes
Sherr J, Cengiz E, Van Name M, Weinzimer S, Tamborlane W. Future Drug Treatments for Type 1 Diabetes. 2016, 985-999. DOI: 10.1002/9781118924853.ch66.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInsulin analoguesDiabetes mellitusContinuous subcutaneous insulin infusion pumpType 2 diabetes mellitusType 1 diabetes mellitusInsulin deliveryBasal insulin analoguesNew treatment optionsFuture drug treatmentsAvailable insulin analoguesMore rapid absorptionClosed-loop deliveryDaily diabetes careAvailable insulin preparationsInsulin infusion pumpIntranasal glucagonInsulin therapyGlycemic controlAdjunctive agentsAvailable therapiesInjected medicationsDiabetes careTreatment optionsContinuous glucose monitorDrug treatment